within Pharmacolibrary.Drugs.ATC.L;

model L03AB12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.034 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 900 / 1000000,
    adminCount     = 1,
    Vd             = 0.005900000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Albinterferon alfa-2b is a recombinant fusion protein of human albumin and interferon alfa-2b developed as a long-acting form of interferon for the treatment of chronic hepatitis C infection. It was intended to offer less frequent dosing schedules compared to traditional pegylated interferons, but its development was discontinued and it is not approved or in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates for healthy adult subjects and patients with chronic hepatitis C, reported after subcutaneous administration.</p><h4>References</h4><ol><li><p>Rustgi, VK (2009). Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. <i>Current medical research and opinion</i> 25(4) 991–1002. DOI:<a href=&quot;https://doi.org/10.1185/03007990902779186&quot;>10.1185/03007990902779186</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19275518/&quot;>https://pubmed.ncbi.nlm.nih.gov/19275518</a></p></li><li><p>Riggs, MM, et al., &amp; Stein, DS (2012). Population pharmacokinetics and exposure-response of albinterferon alfa-2b. <i>Journal of clinical pharmacology</i> 52(4) 475–486. DOI:<a href=&quot;https://doi.org/10.1177/0091270011399576&quot;>10.1177/0091270011399576</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21551316/&quot;>https://pubmed.ncbi.nlm.nih.gov/21551316</a></p></li><li><p>Serra, DB, et al., &amp; Stein, DS (2011). Single-dose pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers. <i>Antimicrobial agents and chemotherapy</i> 55(2) 473–477. DOI:<a href=&quot;https://doi.org/10.1128/AAC.00626-10&quot;>10.1128/AAC.00626-10</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21098255/&quot;>https://pubmed.ncbi.nlm.nih.gov/21098255</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L03AB12;
